title: The complex clinical picture of side effects to anticoagulation.
abstract: Inflammatory plaques at injection sites are frequent side effects of heparin treatment and a clinical symptom of delayed-type hypersensitivity (DTH) to heparin. In most cases, changing the subcutaneous therapy from unfractionated to low-molecular-weight heparin or treatment with heparinoids does not provide improvement because of extensive cross-reactivity. Because of their completely different chemical structure, hirudins are a safe alternative for anticoagulation. Despite DTH to subcutaneously injected heparins, patients tolerate heparin intravenously. Therefore, in case of therapeutic necessity and DTH to heparins, the simple shift from subcutaneous to intravenous heparin administration is justified. Skin necrosis is a rare complication of anticoagulation. Heparin-induced skin necrosis is 1 of the symptoms of immune-mediated heparin-induced thrombocytopenia and should result in the immediate cessation of heparin therapy to prevent potentially fatal thrombotic events. This is in contrast to coumarin-induced skin necrosis, where therapy may be continued or restarted at a lower dose.
authors.affiliation: Allergy Unit, Department of Dermatology, University of Würzburg, Josef Schneider Strasse 2, 97080 Würzburg, Germany. trautmann_a@klinik.uni-wuerzburg.de
authors.forename: Axel
authors.initials: A
authors.lastname: Trautmann
authors.forename: Cornelia S
authors.initials: CS
authors.lastname: Seitz
mesh_terms: D000707:Anaphylaxis / Q000139:chemically induced; D000925:Anticoagulants / Q000009:adverse effects*; D003374:Coumarins / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D005343:Fibrinolytic Agents / Q000009:adverse effects; D000077425:Fondaparinux; D006493:Heparin / Q000009:adverse effects*; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects; D006629:Hirudins / Q000009:adverse effects; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000139:chemically induced; D011134:Polysaccharides / Q000009:adverse effects; D013917:Thrombin / Q000037:antagonists & inhibitors; D013921:Thrombocytopenia / Q000139:chemically induced*; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D003374:Coumarins; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006629:Hirudins; D011134:Polysaccharides; D014812:Vitamin K; D006493:Heparin; C030123:coumarin; D013917:Thrombin; D000077425:Fondaparinux